TRCT
IMMX icon

Tower Research Capital (TRC)’s Immix Biopharma IMMX Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,163
Closed -$63.6K – 5323
2025
Q4 		$63.6K Buy
+12,163
New +$50.1K ﹤0.01% 2250
2025
Q3 		– Sell
-131
Closed -$271 – 5403
2025
Q2 		$271 Sell
131
-340
-72% -$684 ﹤0.01% 5074
2025
Q1 		$791 Buy
471
+290
+160% +$547 ﹤0.01% 4830
2024
Q4 		$398 Sell
181
-2,929
-94% -$5.35K ﹤0.01% 5287
2024
Q3 		$4.63K Sell
3,110
-876
-22% -$1.76K ﹤0.01% 4467
2024
Q2 		$7.89K Sell
3,986
-1,710
-30% -$3.93K ﹤0.01% 4416
2024
Q1 		$17.5K Buy
5,696
+5,119
+887% +$19.8K ﹤0.01% 3119
2023
Q4 		$3.99K Buy
+577
New +$2.61K ﹤0.01% 5011
2023
Q3 		– Sell
-120
Closed -$323 – 6077
2023
Q2 		$323 Sell
120
-6,255
-98% -$13.1K ﹤0.01% 5689
2023
Q1 		$12K Buy
6,375
+4,019
+171% +$8.88K ﹤0.01% 4087
2022
Q4 		$5K Buy
2,356
+2,106
+842% +$2.81K ﹤0.01% 4872
2022
Q3 		$0 Buy
+250
New +$546 ﹤0.01% 6260

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Tower Research Capital (TRC)'s IMMX Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Immix Biopharma (IMMX) in Q1 2026, closing a stake of 12,163 shares — an estimated $63.6K sold.

Tower Research Capital (TRC) first reported a position in IMMX in Q3 2022 and held it in 12 quarters. The position peaked at $63.6K in Q4 2025. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Immix Biopharma position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 12,163 Immix Biopharma shares in Q1 2026, an estimated $63.6K.
  • Tower Research Capital (TRC) first reported a position in Immix Biopharma in Q3 2022 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s Immix Biopharma position peaked at $63.6K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.